US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
JPH10500944A
(en)
*
|
1994-05-05 |
1998-01-27 |
メルク シヤープ エンド ドーム リミテツド |
Morpholine derivatives and their use as antagonists of tachykinins
|
PT777659E
(en)
*
|
1994-08-15 |
2001-09-28 |
Merck Sharp & Dohme |
MORPHINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
|
GB9417956D0
(en)
*
|
1994-09-02 |
1994-10-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9426104D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Use of surfactants and emulsions
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9513972D0
(en)
*
|
1995-07-08 |
1995-09-06 |
Merck Sharp & Dohme |
Pharmaceutical compositions
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5891875A
(en)
*
|
1996-05-20 |
1999-04-06 |
Eli Lilly And Company |
Morpholinyl tachykinin receptor antagonists
|
WO1998002158A1
(en)
|
1996-07-17 |
1998-01-22 |
Merck & Co., Inc. |
Alteration of circadian rhythmicity with a tachykinin antagonist
|
US6117855A
(en)
*
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
CA2273786A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating stress disorders
|
CA2273785A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Raymond Baker |
Use of nk-1 receptor antagonists for treating severe anxiety disorders
|
AU734860B2
(en)
*
|
1996-12-02 |
2001-06-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
AU736042B2
(en)
*
|
1996-12-02 |
2001-07-26 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
CA2273807A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating schizophrenic disorders
|
DE69732133T2
(en)
*
|
1996-12-02 |
2005-12-22 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Use of NK-1 receptor antagonists for the treatment of major depression
|
WO1998024444A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating substance use disorders
|
JP2001507678A
(en)
*
|
1996-12-02 |
2001-06-12 |
メルク シヤープ エンド ドーム リミテツド |
Use of an NK-1 receptor antagonist for the treatment of movement disorders
|
JP2001504851A
(en)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
Use of an NK-1 receptor antagonist for the treatment of sexual dysfunction
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
CA2273856A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
GB9700555D0
(en)
*
|
1997-01-13 |
1997-03-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
CA2287487A1
(en)
*
|
1997-04-24 |
1998-10-29 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating eating disorders
|
WO1999007375A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
US5972938A
(en)
*
|
1997-12-01 |
1999-10-26 |
Merck & Co., Inc. |
Method for treating or preventing psychoimmunological disorders
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
GB9810092D0
(en)
*
|
1998-05-11 |
1998-07-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
JP2002517446A
(en)
*
|
1998-06-11 |
2002-06-18 |
メルク シャープ エンド ドーム リミテッド |
Use of an NK-1 receptor antagonist for the treatment of a mental disorder
|
GB9812617D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812664D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812662D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
WO1999064010A1
(en)
*
|
1998-06-11 |
1999-12-16 |
Merck Sharp & Dohme Limited |
Use of a nk-1 receptor antagonist for treating psychiatric disorders
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
WO2000026215A1
(en)
*
|
1998-10-30 |
2000-05-11 |
Merck & Co., Inc. |
Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine
|
AU1230000A
(en)
*
|
1998-10-30 |
2000-05-22 |
Merck & Co., Inc. |
Linear process for the preparation of a morpholine compound
|
KR100514236B1
(en)
|
1999-02-24 |
2005-09-13 |
에프. 호프만-라 로슈 아게 |
Phenyl- and pyridinyl derivatives
|
DK1394150T3
(en)
|
1999-02-24 |
2011-03-21 |
Hoffmann La Roche |
4-phenylpyridine derivatives and their use as NK-1 receptor antagonists
|
PL350428A1
(en)
|
1999-02-24 |
2002-12-16 |
Hoffmann La Roche |
3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
US6274588B1
(en)
|
1999-05-31 |
2001-08-14 |
Hoffmann-La Roche Inc. |
4-phenyl-pyrimidine derivatives
|
JO2308B1
(en)
|
1999-05-31 |
2005-09-12 |
اف. هوفمان- لاروش أيه جي |
5-phenyl purinidine derivatives
|
CA2388202A1
(en)
|
1999-10-29 |
2001-05-10 |
Merck & Co., Inc. |
Polymorphic form of a tachykinin receptor antagonist
|
DK1103545T3
(en)
*
|
1999-11-29 |
2004-03-15 |
Hoffmann La Roche |
2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-N- (6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl) -isobutyramide
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
AR030284A1
(en)
|
2000-06-08 |
2003-08-20 |
Merck & Co Inc |
PROCESS FOR THE SYNTHESIS OF (2R, 2-ALFA-R, 3A) -2- [1- (3,5-BIS (TRIFLUOROMETIL) PHENYL) ETOXI] -3- (4-FLUOROPHENIL) -1,4-OXAZINE; SUCH COMPOUND AND ITS POLYMORPHIC FORMS
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
AU2001269749A1
(en)
*
|
2000-06-09 |
2001-12-24 |
Merck And Co., Inc. |
Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
|
DK1303490T3
(en)
|
2000-07-14 |
2008-08-25 |
Hoffmann La Roche |
N-oxides as NK1 receptor antagonic products of 4-phenyl-pyridine derivatives
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0020721D0
(en)
*
|
2000-08-22 |
2000-10-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
YU39503A
(en)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Pyrimidine derivatives
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
ATE366576T1
(en)
|
2003-01-31 |
2007-08-15 |
Hoffmann La Roche |
NEW CRYSTAL MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-6-(1,1-DIOXO-1LAMDA-6-
|
WO2005002577A1
(en)
|
2003-07-03 |
2005-01-13 |
F. Hoffmann-La Roche Ag |
Dual nk1/nk3 antagonists for treating schizophrenia
|
US7288658B2
(en)
*
|
2003-07-15 |
2007-10-30 |
Hoffmann-La Roche Inc. |
Process for preparation of pyridine derivatives
|
ES2246687B2
(en)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
USE OF NON-PEPTIDIC ANTAGONISTS OF NK1 RECEPTORS FOR THE PRODUCTION OF APOPTOSIS IN TUMOR CELLS.
|
KR101412339B1
(en)
|
2004-07-15 |
2014-06-25 |
알바니 몰레큘라 리써치, 인크. |
Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
BRPI0518396A2
(en)
|
2004-12-27 |
2008-11-18 |
Eisai R&D Man Co Ltd |
Anti-Dementia Drug Stabilization Method
|
KR100902425B1
(en)
|
2005-02-22 |
2009-06-11 |
에프. 호프만-라 로슈 아게 |
Antagonists
|
MX2007011489A
(en)
|
2005-03-23 |
2007-10-11 |
Hoffmann La Roche |
Metabolites for nk-i antagonists for emesis.
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
US7956050B2
(en)
|
2005-07-15 |
2011-06-07 |
Albany Molecular Research, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
BRPI0616108A2
(en)
|
2005-09-23 |
2011-06-07 |
Hoffmann La Roche |
dosage formulation
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
EP2266980A1
(en)
*
|
2005-10-05 |
2010-12-29 |
Ranbaxy Laboratories Limited |
Polymorphic form of aprepitant intermediate
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
PL2336120T3
(en)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
CA2676357A1
(en)
|
2007-01-24 |
2008-07-31 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
DE602008001983D1
(en)
|
2007-04-20 |
2010-09-09 |
Hoffmann La Roche |
PYRROLIDINE DERIVATIVES AS DOUBLE NK1 / NK3 RECEPTOR ANTAGONISTS
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
ES2367464T3
(en)
|
2007-08-07 |
2011-11-03 |
F. Hoffmann-La Roche Ag |
PYRROLIDINE-ARYL-ETHERES AS NK3 RECEPTOR ANTAGONISTS.
|
EP2254420A4
(en)
|
2008-02-20 |
2012-02-15 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
WO2009111354A2
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2010132487A1
(en)
|
2009-05-12 |
2010-11-18 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
US9034899B2
(en)
|
2009-05-12 |
2015-05-19 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
KR101830447B1
(en)
|
2009-05-12 |
2018-02-20 |
알바니 몰레큘라 리써치, 인크. |
7-([1,2,4]TRIAZOLO[1,5-α]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
PE20121172A1
(en)
|
2009-10-14 |
2012-09-05 |
Merck Sharp & Dohme |
PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
ES2376564B1
(en)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
USE OF ANTIBODIES AGAINST NK1, NK2 AND / OR NK3 RECEPTORS, TO PRODUCE APOPTOSIS IN TUMOR CELLS AND TO MODIFY STRAMA, IMMUNITY AND INTRA AND PERITUMORAL VASCULARIZATION, AS TREATMENT OF CANCER.
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
IN2013MN02170A
(en)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2837381A4
(en)
|
2011-12-13 |
2015-12-09 |
Servicio Andaluz De Salud |
Use of agents that alter the peritumoral environment for the treatment of cancer
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
MX363243B
(en)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Compositions and methods for treating cancer.
|
BR112015013611A2
(en)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
compound and pharmaceutical composition
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
ES2493693B1
(en)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Method to predict or predict the response of a human subject suffering from cancer to treatment with an NK1 receptor antagonist
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
ES2541870B1
(en)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Use of NK1 non-peptide antagonists in a given dose for cancer treatment
|
EP3091977A2
(en)
*
|
2013-12-30 |
2016-11-16 |
Oncoprevent GmbH |
Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
WO2017211663A1
(en)
|
2016-06-06 |
2017-12-14 |
Helsinn Healthcare Sa |
Physiologically balanced injectable formulations of fosnetupitant
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|